Skip to main content
. Author manuscript; available in PMC: 2019 Sep 26.
Published in final edited form as: N Engl J Med. 2016 Dec 6;376(7):629–640. doi: 10.1056/NEJMoa1612674

Figure 1 (facing page). Duration of Progression-free Survival, According to Subgroup.

Figure 1 (facing page).

Shown are Kaplan–Meier estimates of the duration of progression-free survival as assessed by investigators in the intention-to-treat population (Panel A), in patients with central-nervous-system (CNS) metastases (Panel B), and in patients with EGFR T790M–positive status in both tumor and plasma (Panel C). The tick marks indicate censored data. Progression events that occurred after two or more missed visits (i.e., 14 weeks) after the last assessment were censored at the last assessment, according to Response Evaluation Criteria in Solid Tumors. CI denotes confidence interval.